1. Academic Validation
  2. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

  • Cancer Res. 2002 Sep 1;62(17):4916-21.
Ryohei Furumai 1 Akihisa Matsuyama Nobuyuki Kobashi Kun-Hyung Lee Makoto Nishiyama Hidenori Nakajima Akito Tanaka Yasuhiko Komatsu Norikazu Nishino Minoru Yoshida Sueharu Horinouchi
Affiliations

Affiliation

  • 1 Department of Biotechnology, The University of Tokyo, Tokyo 113-8657, Japan.
PMID: 12208741
Abstract

FK228 is a histone deacetylase (HDAC) inhibitor, the molecular mechanism of inhibition of which has been unknown. Here we show that reduction of an intramolecular disulfide bond of FK228 greatly enhanced its inhibitory activity and that the disulfide bond was rapidly reduced in cells by cellular reducing activity involving glutathione. Computer modeling suggests that one of the sulfhydryl groups of the reduced form of FK228 (redFK) interacts with the active-site zinc, preventing the access of the substrate. HDAC1 and HDAC2 were more strongly inhibited by redFK than HDAC4 and HDAC6. redFK was less active than FK228 in inhibiting in vivo HDAC activity, due to rapid inactivation in medium and serum. Thus, FK228 serves as a stable prodrug to inhibit class I enzymes and is activated by reduction after uptake into the cells. The glutathione-mediated activation also implicates its clinical usefulness for counteracting glutathione-mediated drug resistance in chemotherapy.

Figures
Products